Home > Research Areas > Cancer > Blood Cancer
Cat. No. Product name CAS No.
DCC-073 Gossypol-acetic acid

>98%,Standard References

12542-36-8
DC11631 INCB040093

A novel potent, selective, orally available PI3Kδ inhibitor with IC50 of 31 nM.

1262440-25-4
DC11716 XL-844

A potent, specific, orally available, ATP‑competitive inhibitor of Chk1 and Chk2 with Ki of 2.2 nM and 0.07 nM, respectively.

631864-00-1
DC5027 ABC294640(Opaganib) Featured

ABC294640 is an orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity.

915385-81-8
DC4127 ABT-263 (Navitoclax) Featured

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤ 1 nM, respectively.

923564-51-6
DC9660 Acalabrutinib(ACP196) Featured

Acalabrutinib (ACP-196) is a second-generation, selective, irreversible inhibitor of BTK.

1420477-60-6
DC8760 Acalisib Featured

Acalisib (GS-9820) is a potent and selective inhibitor of PI3Kδ with IC50 value of 12.7 nM.

870281-34-8
DC8051 AG-120 (Ivosidenib) Featured

AG-120 is a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein.

1448347-49-6
DC8374 AG-221(Enasidenib) Featured

AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein.

1446502-11-9
DC2096 AG490 Featured

AG-490 (Tyrphostin B42) is an inhibitor of EGFR, ErbB2 and JAK2 with IC50 of 0.1 μM, 13.5 μM, and ~10 μM, respectively.

133550-30-8
DC10439 Vorasidenib (AG881) Featured

AG-881 is a potent and selective orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1) in the cytoplasm and type 2 (IDH2).

1644545-52-7
DC9366 AMG 900 Featured

AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM; >10-fold selective for Aurora kinases than p38α, Tyk2, JNK2, Met and Tie2.

945595-80-2
DC6311 Pomalidomide

An inhibitor of LPS-induced TNFαrelease.Pomalidomide is thalidomide derivative that displays inhibition of LPS-induced TNFα release. Shows immunomodulator and anticancer effects.

19171-19-8
DC1020 Ponatinib (AP24534)

AP24534 is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.

943319-70-8
DC8275 Apilimod Featured

Apilimod(STA 5326) is a potent IL-12/IL-23 inhibitor, IL-12 production in cultures of IFN-r/LPS–stimulated human PBMCs is strongly inhibited by STA-5326 with an IC50 of 10 nM.

541550-19-0
DC8664 APTO-253

APTO-253 is a novel small molecule with potent anti-tumor activity in cancer cells via induction of the gene that expresses the Krüppel-like factor 4 (KLF4) master transcription factor, leading to cell cycle inhibition and programmed cell death.

916151-99-0
DC9972 ARQ-092 Featured

ARQ 092 is an oral activie, potent and selective AKT inhibitor with IC50 values: 5.0 nM (AKT1); 4.5 nM (AKT2); 16 nM (AKT3).

1313881-70-7
DC10975 ARQ-531 Featured

ARQ-531 is a potent, reversible, orally available inhibitor of both wild type and C481S-mutant BTK kinase with IC50 of 0.85 and 0.39 nM,

2095393-15-8
DC7359 ASP3026 Featured

ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM.

1097917-15-1
DC2015 AT-101 (AT101)

AT-101 is a BH3 mimetic known to be a potent inhibitor of antiapoptotic Bcl-2 family members.

866541-93-7
DC9676 AT7519 Featured

AT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM; less potent to CDK3 and little active to CDK7.

844442-38-2
DC1025 AT7519 HCL Featured

AT7519 is a novel multi-CDK inhibitor for CDK1/cyclin B, CDK2/Cyclin A, CDK3/Cyclin E, CDK4/Cyclin D1, CDK5/p35 and CDK6/Cyclin D3 with IC50 of 210 nM, 47 nM, 360 nM, 100 nM, 13 nM and 170 nM, respectively.

902135-91-5
Page 1 / Total 8 FirstPrevNextLastGoto